Episode 71: The Spice must FLOW!

The Filtrate:

Joel Topf

Swapnil Hiremath

Josh Waitzman

Nayan Arora

Sophia Ambruso

With Special Guest:

Brendon Neuen Super smart guy and clinical trialist

Vlado Perkovic Lead author of FLOW and friend of NephJC

Editor

Joel Topf

Show Notes

The manuscript (NEJM): Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

The acronym FLOW from the title: evaluate renal Function with semagLutide Once Weekly (Twitter)

Joel wrote a blog post prior to the FLOW publication to try to set the table: Peeking Inside Schrödinger’s Box

Brendon’s Neuen’s tweet about total versus chronic slope (X | Twitter)

Modification of Association of Cystatin C With Kidney and Cardiovascular Outcomes by Obesity (Science Direct)

Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials (PubMed)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis (Frontiers in Pharmacology)

Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials (PubMed)

Proteinuria Thresholds Are Irrational: A Call for Proteinuria Indexing (Nephron Clinical Practice)

Frank Harrel on why the NNT sucks (data methods)

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells (PubMed)

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance (PubMed)

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial (PubMed)

Doctors are like the pyromaniac fireman (PBFluids)

Suggest topics for NephMadness (Twitter)

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) (PubMed)

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial (